Knowledge Hub
Real-time biotech intelligence, industry statistics, and a comprehensive glossary — curated from peer-reviewed sources and updated continuously. No paywalls. No fluff.
Showing 12 insights
Only 1 in 10 drugs that enter clinical trials ever reach patients.
The overall probability of clinical success from Phase I to FDA approval is approximately 7.9%. Most failures occur in Phase II due to lack of efficacy — not safety.
SBIR/STTR awards have funded over $50B in early-stage innovation since 1982.
The federal SBIR/STTR program remains the largest source of non-dilutive early-stage funding for US small businesses. Phase II awards now reach up to $2M per project.
70% of biotech acquisitions fail to create shareholder value.
McKinsey analysis of 2,500+ deals shows that most M&A destroys value due to integration failures, overvalued pipelines, and cultural misalignment. Due diligence quality is the #1 differentiator.
AI-designed molecules are entering Phase II trials — but validation gaps remain.
As of 2024, 15+ AI-designed drug candidates have entered clinical trials. However, fewer than 30% of AI-generated leads have published experimental validation data, creating significant IP and reproducibility risk.
Up to 50% of clinical trial data is never published.
Publication bias means negative and inconclusive results are systematically suppressed. This leads to duplicated failed experiments across the industry, wasting an estimated $28B annually.
FDA Accelerated Approval has approved 260+ drugs since 1992.
The pathway has been transformative for oncology and rare diseases, cutting approval timelines by 3–5 years. Post-market confirmatory trial requirements were strengthened by the Omnibus Act of 2023.
Average cost to develop a new drug: $2.6 billion.
The Tufts Center for the Study of Drug Development estimates total capitalized cost at $2.6B, including the cost of failures. This figure has grown 145% in inflation-adjusted terms since 2003.
Biomarker-stratified trials are 2.5x more likely to succeed.
Trials using validated biomarkers for patient selection show significantly higher Phase II-to-III transition rates. Precision medicine approaches are now standard in oncology and increasingly adopted in CNS and metabolic disease.
Burnout affects 52% of biotech and pharma professionals.
A 2023 survey found that more than half of life sciences professionals report burnout symptoms, with clinical operations and regulatory affairs teams most affected. Organizational wellness programs reduce turnover by up to 28%.
Patent cliffs will expose $200B+ in branded drug revenue by 2030.
Major blockbusters including Humira, Eliquis, and Keytruda face patent expiry through 2028–2030. This creates both generic competition risk and licensing/acquisition opportunities for pipeline assets.
Orphan drugs now represent 50% of all FDA approvals.
The rare disease space has become the dominant approval category. Orphan designation provides 7 years of market exclusivity, 50% tax credits on clinical trial costs, and waived FDA user fees — making it the most favorable regulatory pathway.
The global CRO market will reach $96B by 2028.
Outsourcing of clinical and preclinical research continues to accelerate. Small biotechs now outsource 70%+ of their R&D activities. CRO selection and contract negotiation are critical strategic decisions.
Go/No-Go Decision Tool
Apply this knowledge to your program. Get an evidence-based evaluation in minutes.
Start EvaluationEducational Disclaimer: All content on this Knowledge Hub is provided for educational and informational purposes only. Statistics and data are sourced from publicly available peer-reviewed publications, government reports, and industry analyses as cited. Bridge BioHealth LLC does not guarantee the accuracy, completeness, or timeliness of third-party data. Nothing on this page constitutes investment advice, regulatory guidance, legal counsel, or a recommendation to pursue or abandon any specific drug development program. Always consult qualified professionals before making strategic, financial, or regulatory decisions.